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Ageinga b s t r a c t
The diabetic drug rosiglitazone was reported to improve glucose tolerance in insulin-resistant
ApoE3 but not ApoE4 knock-in mice. We therefore examined whether apolipoprotein E (ApoE)
has genotype-speciﬁc effects on liver insulin function. At 12 weeks, no difference in liver insulin sig-
naling was detected between fasting ApoE3 and ApoE4 mice. At 72 weeks however, ApoE4 mice had
lower IRS-1 and PI3K expression, and reduced Akt phosphorylation. This decline was associated with
lower insulin and higher glucose in ApoE4 mouse liver. Liver cholesterol was not affected. These
results show that ApoE4 expression reduces liver insulin signaling and insulin levels, leading to
higher glucose content.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Human apolipoprotein E (ApoE) exists in 3 isoforms, E2, E3 and
E4 [1,2]. These isoforms differ by amino acid substitutions at two
positions (residues 112 and 158) [3].
ApoE is synthesized in various organs [4] and high expression is
detected in the liver [5]. This protein is extensively studied as a
group of lipid carrier molecules vital to the cholesterol homeostasis
of the body [5].
However, emerging studies suggest that ApoE has other func-
tions beyond cholesterol metabolism [1,6]. ApoE4 carriers have
shown to experience greater age-related reduction in cerebral glu-
cose metabolism [7–9], and intra-nasal insulin improves cognition
in ApoE3 [10,11] but not ApoE4 non-demented elderly subjects
[12]. This shows an isoform-dependent role in brain glucose
metabolism and insulin function.
In non-diabetic subjects, the presence of ApoE4 did not affect
fasting glucose level [13]. But, the effect of ApoE4 on fasting glu-
cose and insulin levels in diabetic subjects is unknown. However,obese men with the ApoE4 genotype have higher insulin and glu-
cose levels than obese men without the ApoE4 genotype [14].
In diet-induced insulin resistant ApoE3 and ApoE4 knock-in (KI)
mice, the insulin sensitizer rosiglitazone only improved glucose
tolerance in ApoE3 KI mice [15,16]. This suggests that ApoE could
have a genotype-dependent effect on peripheral insulin function.
To understand ApoE role on peripheral insulin function, we
have conducted this study to examine the age-related effects of




The experimental protocol (#009/10) involving the laboratory
mice used in this study was approved by the Institutional Animal
Care and Use Committees (IACUC) at the National University of
Singapore. The human apolipoprotein E3 and E4 knock-in (KI) mice
were created as described [17] and were purchased from Taconic.
Brieﬂy, the endogenous mouse ApoE gene was replaced by the hu-
man APOE genomic fragments via homologous recombination. The
mice were kept on 2018 Teklad Global 18% Protein Rodent Diet
(Harland Laboratories). Mice were fasted for 12 h prior to exper-
iments. All experiments were performed on at least three (nP 3)
fasted female homozygous ApoE3 and ApoE4 mice at 12 and
72 weeks of age.
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The method used to homogenize the mouse liver tissues is the
same as described in our earlier study [18]. Brieﬂy, mouse liver tis-
sues were snapped frozen in liquid nitrogen when harvested and
the wet weight of the tissues (in mg) were determined using an
electronic balance. Twenty percent (w/v) liver homogenates were
prepared with 1 cell lysis buffer (Cell Signaling Technology) with
protease inhibitors cocktail (Roche Diagnostic).
The cell lysis buffer contains sodium orthovanadate, pyrophos-
phate and glycerophosphate, which can acts as phosphatase
inhibitors. Lysates were then homogenized using a hand held
motorized pestle (Sigma–Aldrich, St. Louis, USA) for 30 s on ice.
Tissue lysates were subsequently centrifuged at 30,000g for
30 min under 4C. The soluble portion of the lysates was collected
for analysis.
2.3. Protein quantiﬁcation of lysates
The method used to quantify the mouse liver homogenates is
the same as described in our earlier study [18]. Brieﬂy, tissue ly-
sates were quantiﬁed using the Pierce™ MicroBCA assay kit (Ther-
moFisher Scientiﬁc, Waltham, USA) in a 96-well microplate format.
Lysates were diluted in PBS and the working reagent was prepared
and added in accordance to the manufacturer’s instructions. Sam-
ples were then incubated at 37 C for 30 min before reading the
absorbance values at 562 nm. Protein concentrations of samples
were calculated based on a standard curve constructed from a
range of BSA standards. The liver tissue lysates were aliquoted
and stored at 80 C.
2.4. Immunoblot analysis
The method used to perform immunoblotting is the same as
described in our earlier study [18]. Soluble liver proteins from ly-
sate samples were heated at 95 C for 5 min. Protein samples
were then centrifuged at 14,000g for 2 min on a bench top centri-
fuge before they were loaded on a 7.5–10% Tris–glycine poly-
acrylamide gel. The Precision Plus protein™ standard (Bio-Rad
Laboratories, Hercules, California USA) was used as a molecular
weight standard and run together with the samples on the same
piece of gel.
The separated proteins were transferred onto a nitrocellulose
membrane, probed with the respective antibodies and exposed to
horseradish peroxidase (HRP)-conjugated secondary antibodies.
The reactive protein bands were visualized by chemiluminescence
on the Image Station 4000R (Carestream Health Inc) using the
SuperSignal West Dura Substrate (Pierce) system.
Immunoblotting of b-actin using a rabbit polyclonal antibody
that binds to the C-terminal of b-actin (Sigma) was included in
all western blot analysis to ensure comparable protein loading.
The primary antibodies used include anti-huApoE (Santa Cruz Bio-
techn, Cat# 13521), anti-IRS1 (Cell Signaling Technology, Cat#
2382), anti-PI3K/p85 (Cell Signaling Technology, Cat#4257), anti-
PI3K/p110 (Cell Signaling Technology, Cat# 4249), anti-Akt (Cell
Signaling Technology, Cat# 4691), anti-pAkt(S473) (Cell Signaling
Technology, Cat# 4060), and anti-pAkt(T308) (Cell Signaling Tech-
nology, Cat# 2965).
Densitometry analysis was performed [18] by measuring the
optical densities of the targeted protein bands relative to the
endogenous b-actin level from the same liver sample. For protein
phosphorylation, the optical densities of the phosphorylated pro-
tein bands were measured relative to the targeted total protein le-
vel from the same liver sample. The analysis was performed using
the NIH ImageJ software.2.5. Glucose assay
The method used to measure tissue glucose level is the same as
described in our recent study [19]. Total liver glucose content was
measured using the amplex red glucose assay kit (Life Technolo-
gies) following the instructions provided by the manufacturer.
Brieﬂy, liver lysate sample was mixed with equal volume of am-
plex red working reagent, and the reaction mixture was then incu-
bated for 30 min at room temperature in the dark. The ﬂuorescence
values were read at an excitation wavelength of 545 nm and an
emission wavelength of 590 nm. A series of glucose standards were
prepared and run alongside the mouse liver samples.
2.6. Insulin assay
The method used to measure tissue insulin level is the same as
described in our recent study [19]. Total liver insulin content was
measured using the sandwich ELISA mouse insulin assay system
(Millipore) following the instructions provided by the manufac-
turer. Brieﬂy, liver lysates were added to microtiter plate well
pre-coated with anti-insulin antibody. After incubation and wash-
ing, a biotinylated anti-insulin antibody was added. This biotinyla-
ted antibody reacts against a distinctive epitope to that of the
coated anti-insulin. The reaction was incubated for 15 min and
the absorbance was read at 370 nm. The stop solution provided
by the assay kit was added to the sample when the absorbance
was read at 1.8. Immunoreactivity was immediately determined
by measuring the absorbance at 450 nm and 590 nm.
2.7. Statistical analysis
Signiﬁcant differences were analyzed using the same method
described in our recent study [19]. Statistical analysis was per-
formed using two-tailed Student’s t-test. A p value of <0.05 is con-
sidered signiﬁcant.
3. Results
3.1. Lower liver insulin receptor substrate protein and PI3K expression
in aged ApoE4 KI mice
While ApoE role in liver cholesterol metabolism is well charac-
terized [1], the effects of this protein (and its polymorphism) on li-
ver insulin signaling has not been examined. We therefore decided
to determine if ApoE polymorphism can affect hepatic insulin sig-
naling in ageing ApoE3 and ApoE4 knock-in (KI) mice.
At 12 weeks, insulin receptor substrate 1 (IRS1) expression does
not differ between fasting ApoE3 and ApoE4 mice (Fig. 1A). At
72 weeks however, IRS1 expression is non-detectable in the fasting
ApoE4 KI mice.
We then examined the expression of the catalytic subunit
(p110) and the regulatory subunit (p85) of phosphatidylinositol
3-kinase (PI3K). At 12 weeks, PI3K/p110 and PI3K/p85 expression
were comparable between ApoE3 and ApoE4 mice. In the aged
(72 weeks) fasting ApoE4 mice however, PI3K/p110 and PI3K/p85
expression were reduced by 70% (Fig. 1C) and 44% (Fig. 1D) respec-
tively as compared to fasting ApoE3 mice.
3.2. Reduced Akt phosphorylation in the liver of ApoE4 mice
We next determined if the aberrant IRS1 and PI3K expression
(Fig. 1) affects downstream Akt expression and phosphorylation
(Fig. 2). Liver Akt expression did not differ between ApoE3 and
ApoE4 mice at 12 weeks and at 72 weeks (Fig. 2B). Akt
phosphorylation at Serine-473 (S473) and at Threonine-308
Fig. 1. Hepatic insulin receptor substrate and PI3K proteins expression in ApoE knock-in mice. (A) Western blot analysis of insulin receptor substrate-1 (IRS1), PI3K/p85 and
PI3K/p110 levels in the liver of ApoE3 and ApoE4 mice at 12 and 72 weeks of age. b-actin was immunoblotted to ensure similar gel loading of the starting material in each
sample. The blot is a representative of three independent experiments. Densitometry analysis of total (B) IRS1, (C) PI3K/p110 and (D) PI3K/p85 level relative to b-actin level in
12 and 72 weeks old ApoE3 (white bar) and ApoE4 (grey bar) mice was performed using the NIH ImageJ software. Each value represents the mean ± SEM for individual mouse
liver sample (n = 3 at each time point for each mouse line). Lower IRS1, PI3K/p85 and PI3K/p110 levels were detected in ApoE4 mice at 72 weeks of age as compared to ApoE3
mice of similar age. (⁄p < 0.03; ⁄⁄p < 0.008, using Student’s t-test.)
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mice (Fig. 2A).
However, in 72 weeks fasting ApoE4 mice, Akt phosphorylation
at S473 and at T308 were signiﬁcantly reduced by 44% and 53%
respectively as compared to fasting ApoE3 mice at similar age
(Figs. 2C and D).
3.3. Liver insulin and glucose in ApoE mice
Changes in IRS1 expression can affect insulin and glucose con-
tents [20–22]. We therefore measured the content of liver glucose
and insulin in the young and aged ApoE3 and ApoE4 mice. In the
12 weeks old fasting ApoE KI mice, we did not detect any signiﬁ-
cant difference in liver insulin and glucose level between the two
mouse lines (Fig. 3). However, the liver insulin of the 72 weeks
old fasting ApoE4 mice (dotted line) was 37% lower than the fast-
ing ApoE3 mice at similar age (bold line). Liver glucose content was
also signiﬁcantly affected in the aged fasting ApoE mice. The liver
glucose in the aged fasting ApoE4 mice (grey bar) was 27% higher
than the fasting aged ApoE3 mice (white bar).
3.4. Liver cholesterol in ApoE mice
ApoE is a major player in cholesterol metabolism [1]. However,
cholesterol level is only elevated when the ApoE mouse lines are
kept on high-fat diet [17,23,24]. Hence, we did not observe any sig-
niﬁcant change in liver cholesterol content between the fasting
ApoE3 and ApoE4 mice when kept on normal rodent diet (Fig. 4).3.5. Liver ApoE expression
Reduced ApoE levels have been reported in the brain of huA-
poE4 KI mice [25,26], but ApoE expression in the peripheral tissues
including liver has not been examined.
We therefore immunoblotted for ApoE in the liver of fasting
ApoE3 and ApoE4 mice at 12 and 72 weeks of age. As show in
Fig. 5, lower ApoE content was detected in the liver of 12 and
72 weeks old ApoE4 mice as compared to ApoE3 mice at similar
ages. There was a 23% reduction observed in the young ApoE4 mice
and this was further reduced to 71% in the aged ApoE4 mice when
compared to ApoE3 mice at similar ages.
4. Discussion
In diet-induced insulin resistant ApoE3 and ApoE4 KI mice, the
insulin sensitizer rosiglitazone only improves glucose tolerance in
ApoE3 mice [15,16]. In this study using fasting ApoE mice, we are
reporting an ApoE genotype-dependent effect on liver insulin sig-
naling during ageing. In aged mice, we observed that lower ApoE4
expression was linked to lower liver brain insulin signaling and
insulin content, and higher liver glucose level. Liver cholesterol
content however was not affected since the mice were not kept
on high-fat diet [17].
In this study, mice were fasted to trigger a catabolic state when
examining peripheral insulin signaling [27]. This process is meant
to reduce variability in baseline insulin signaling activation during
experiments.
Fig. 2. Akt expression and phosphorylation in the liver of fasting ApoE mice. (A) Immunoblotting of total Akt, phosphorylated Akt (S473) and phosphorylated Akt (T308) in
the liver of ApoE3 and ApoE4 mice at 12 and 72 weeks of age. b-actin was immunoblotted to ensure similar gel loading of the starting material in each sample. The blot is a
representative of three independent experiments. Densitometry analysis of (B) total Akt level relative to b-actin level, (C) phosphorylated Akt(S437) and (D) phosphorylated
Akt(T308) level relative to total Akt level, in 12 and 72 weeks old ApoE3 (white bar) and ApoE4 (grey bar) mice was performed using the NIH ImageJ software. Each value
represents the mean ± SEM for individual mouse liver sample (n = 3 at each time point for each mouse line). Lower Akt phosphorylation at S473 and T308 were detected in
72 weeks ApoE4 mice as compared to ApoE3 mice at similar age. (⁄p < 0.02; ⁄⁄p < 0.04, using Student’s t-test.)
Fig. 3. Analysis of liver insulin and glucose contents in fasting ApoE mice. Higher
glucose (grey bar) and lower insulin (dotted line) were detected in the liver of
72 weeks ApoE4 mice as compared to ApoE3 mice (white bar and bold line) of
similar age. Each value represents the mean ± SEM of duplicate assays for individual
samples (n = 5). (⁄p < 0.02 using Student’s t-test.)
Fig. 4. Analysis of liver cholesterol content in fasting ApoE mice. No signiﬁcant
different in liver cholesterol contents between ApoE3 (white bar) and ApoE4 (grey
bar) mice at 12 and 72 weeks of age was detected. Each value represents the
mean ± SEM of duplicate assays for individual samples (n = 5).
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most non-detectable. Changes in IRS1 had been shown to affect
PI3K/Akt signaling [28,29]. As compared to the aged fasting
ApoE3 mice, lower levels of the catalytic subunit (p110) and the
regulatory subunit (p85) of phosphatidylinositol 3-kinase (PI3K),
and Akt phosphorylation were detected in the liver of aged ApoE4
mice.
One possible mechanism linking IRS1 and PI3K/Akt activation is
ApoE expression. Studies have shown that increasing ApoE expres-
sion will elevate Akt phosphorylation [30]. Hence, the lower Aktphosphorylation in ApoE4 mice could be due to lower ApoE level.
This interaction may also lead to reduced IRS1 expression.
Changes in IRS1 expression can affect insulin and glucose con-
tents [20–22]. The change in liver glucose and insulin levels were
only detected between aged ApoE4 and aged ApoE3 mice. In the
72 weeks old fasting ApoE4 KI mice, lower liver insulin content
was correlated with lower IRS1 and PI3/Akt expression and phos-
phorylation as compared to the aged fasting ApoE3 mice. However,
Fig. 5. Lower human apolipoprotein E (ApoE) level in the liver of ApoE4 knock-in
mice. (A) Western blot and (B) densitometric analysis of liver ApoE levels in ApoE3
(white bar) and ApoE4 (grey bar) knock-in mice at 12 and 72 weeks of age. (A) The
blot is a representative of three independent experiments. b-actin was immuno-
blotted to ensure similar gel loading of the starting material in each sample. (B)
Densitometric analysis was performed the NIH ImageJ software. Each value
represents the mean ± SEM for individual mouse liver sample (n = 3 at each time
point for each mouse line). Liver ApoE level was signiﬁcant reduced in ApoE4 mice
as compared to ApoE3 mice of similar age. (⁄p < 0.02 using Student’s t-test.)
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content and insulin signaling is unknown. Furthermore, it is un-
clear how the lower insulin content contributes to the higher glu-
cose level detected in the liver of the aged ApoE4mice as compared
to ApoE3 mice.
ApoE is extensively studied as a group of lipid carrier molecules
that is vital in the cholesterol homeostasis of the body [5]. How-
ever, emerging studies suggest that ApoE has other functions be-
yond cholesterol metabolism [1,6]. The results in this study have
shown an interplay between ApoE and liver insulin signaling. Pre-
vious study has also detected higher fasting insulin and glucose
levels in obese male ApoE4 carriers as compared to obese men
without the ApoE4 genotype [14]. Taken together, it is possible
that ApoE4-induced impairment in metabolic functions can modu-
late atherosclerosis and cardiovascular disease progression [1].
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